This is a community-generated profile. If you would like to claim it, please .
COMBiNATi careers
The challenges facing doctors and scientists are difficult enough; COMBiNATi uses proprietary technology to bring more efficient and effective workflows to critical research and diagnostics.
The first realized application is a digital PCR platform including a cost effective proprietary plastic disposable and a low cost processing instrument. The platform will offer comparable workflow and running cost as the current gold standard (quantitative PCR, qPCR) and provide higher throughput, sensitivity, and precision. Immediate applications include next generation sequencing library quantification & QC, rare cancer mutation detection, viral load and latent reservoir monitoring, pathogen detection, and many more.
Pipeline projects include bio-mimetic processing consumables, pharma toxicity screening tools, and a digital high resolution melt analysis platform for early sepsis diagnosis.
The first realized application is a digital PCR platform including a cost effective proprietary plastic disposable and a low cost processing instrument. The platform will offer comparable workflow and running cost as the current gold standard (quantitative PCR, qPCR) and provide higher throughput, sensitivity, and precision. Immediate applications include next generation sequencing library quantification & QC, rare cancer mutation detection, viral load and latent reservoir monitoring, pathogen detection, and many more.
Pipeline projects include bio-mimetic processing consumables, pharma toxicity screening tools, and a digital high resolution melt analysis platform for early sepsis diagnosis.
COMBiNATi hasn't added any jobs yet
Get notified when COMBiNATi posts new jobs.
Paul Hung
Founded COMBiNATi. Founded CellASIC (acquired by Millipore). PI/Co-PI of 6 NIH SBIR Grants. Delivered 2 award winning microfluidic platforms to market.
Megan Dueck
As co-founder and Chief Scientific Officer of COMBiNATi I am responsible for maintaining a thorough understanding of precision nucleic acid-based diagnostics.
Andrew Zayac
Founder COMBiNATi• Worked at @CellASIC, @MilliporeSigma, a business of Merck KGaA, Darmstadt, Germany on R&D and NPI.
Ptc Therapeutics • United States • $123k – $154k • 6 days ago
Alexza Pharmaceuticals • Fremont • 1 week ago
Pfizer • New York City • $124k – $207k • 1 week ago
Emerald Therapeutics • Austin • 2 weeks ago
Medtronic • Minneapolis • $95k – $142k • 3 weeks ago
